Drug Trial Radar · NCT05345197
Emicizumab in Patients With Acquired Hemophilia A
Last checked: Nov 19, 2026Latest source record: Nov 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
51
Planned (sponsor's estimate)
Start
Aug 31, 2022
Primary completion
Jul 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- University of WashingtonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Genentech, Inc.
- First posted
- Apr 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).
Conditions
- Acquired Hemophilia A
Interventions
emicizumabDrug
This study design uses emicizumab as a prophylaxis treatment to prevent bleeding for all participants, bypassing agents (with the exception of aPCC) and treatment of concomitant diseases will be given as clinically indicated. All eligible subjects with AHA will receive the same study medication consisting of: two loading doses of the emicizumab on day 1 and 2 followed by once weekly subcutaneous emicizumab injections. Immunosuppressive therapy (IST) will be given concurrently as per investigator discretion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Outcome MeassureTime frame: 12 weeks
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
UCSD Hemophilia and Thrombosis Treatment Center
San Diego, California
Georgetown University
Washington D.C., District of Columbia
Emory University
Atlanta, Georgia
Bleeding and Clotting Disorders Institute
Peoria, Illinois
Indiana Hemophilia and Thrombosis Center, Inc.
Indianapolis, Indiana
Tulane University
New Orleans, Louisiana
Mayo Clinic
Rochester, Minnesota
Washington University
St Louis, Missouri
University of North Carolina
Chapel Hill, North Carolina
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Penn Blood Disorders Program, Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Hemophilia Center of Western Pennsylvania
Pittsburgh, Pennsylvania
University of Vermont Medical Center
Burlington, Vermont
UVA Comprehensive Cancer Center
Charlottesville, Virginia
Washington Center for Bleeding Disorders
Seattle, Washington
Versiti Inc.
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.